SCHEMBL4236448

SCHEMBL4236448

Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1C(=O)NCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 6/20 0.59
AR P10275 12/20 0.58
CNR2 P34972 5/20 0.54
P2RX7 Q99572 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4232821 0.90 AR (0.58) CNR1AR
SCHEMBL4232133 0.90 AR (0.63) CNR1AR
SCHEMBL4227409 0.89 NPC1 (0.57) CNR1AR
SCHEMBL4243205 0.89 AR (0.68) CNR1AR
SCHEMBL4235512 0.89 AR (0.56) AR
SCHEMBL4232743 0.88 AR (0.54) CNR1AR
SCHEMBL4231171 0.88 AR (0.69) CNR1AR
SCHEMBL4303028 0.87 AR (0.60) CNR1AR
SCHEMBL4303521 0.87 AR (0.55) CNR1AR
SCHEMBL4298371 0.86 AR (0.54) CNR1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20090270361-A1 Substituted pyrazole derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
WO-2009119880-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270361-A1 Substituted pyrazole derivatives and use thereof CBR3, CBR1, NOX5 CNR1 26/4885AR 622/4885CNR2 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.